Selected article for: "host cell and increase expression"
Author: Brojakowska, Agnieszka; Narula, Jagat; Shimony, Rony; Bander, Jeffrey
Title: Clinical Implications of SARS-Cov2 Interaction with Renin Angiotensin System
  • Cord-id: 6ph3ykfc
  • Document date: 2020_4_16
    • ID: 6ph3ykfc
    Snippet: Abstract SARS-CoV2 host cell infection is mediated by the binding to angiotensin-converting enzyme 2 (ACE2). Systemic dysregulation observed in SARS-CoV was previously postulated to be due to ACE2/Ang1-7/Mas axis downregulation, increased ACE2 activity was shown to mediate disease protection. Since angiotensin II receptor blockers (ARBs), ACE inhibitors, and mineralocorticoid receptor antagonists (MRAs) increase ACE2 receptor expression, it has been tacitly believed that the use of these agents
    Document: Abstract SARS-CoV2 host cell infection is mediated by the binding to angiotensin-converting enzyme 2 (ACE2). Systemic dysregulation observed in SARS-CoV was previously postulated to be due to ACE2/Ang1-7/Mas axis downregulation, increased ACE2 activity was shown to mediate disease protection. Since angiotensin II receptor blockers (ARBs), ACE inhibitors, and mineralocorticoid receptor antagonists (MRAs) increase ACE2 receptor expression, it has been tacitly believed that the use of these agents may facilitate viral disease, thus they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/Ang1-7/Mas axis and previously demonstrated benefits of lung function improvement in SARS-CoV infections, we hypothesize that the benefits of treatment with renin-angiotensin system inhibitors in SARS-COV2 may outweigh the risks and at the very least should not be withheld.

    Search related documents:
    Co phrase search for related documents
    • ace activity and acute lung failure: 1, 2
    • ace activity and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8
    • ace activity and admission time: 1
    • ace activity and local expression: 1
    • ace activity and lung failure: 1, 2, 3
    • ace activity and lung function: 1
    • ace activity and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • ace activity decrease and activity expression: 1
    • ace enzyme and acid dependent: 1
    • ace enzyme and activity expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • ace enzyme and acute lung failure: 1, 2, 3, 4, 5, 6
    • ace enzyme and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • ace enzyme and acute myocardial injury: 1, 2
    • ace enzyme and admission time: 1, 2
    • ace enzyme and local expression: 1, 2, 3
    • ace enzyme and losartan effect: 1
    • ace enzyme and lung failure: 1, 2, 3, 4, 5, 6, 7, 8
    • ace enzyme and lung parenchyma: 1, 2
    • ace enzyme and magnetic resonance: 1, 2